Merck nears $6 billion deal for Terns Pharma: what it means for oncology stocks

Welcome to Breaking News to Trading Moves. Today’s big story is a healthcare deal headline that could ripple well beyond 2 stocks. Merck is nearing a roughly $6 billion all-cash acquisition of Terns Pharma; a move aimed at strengthening its cancer portfolio as it prepares for Keytruda’s patent expiry in 2028. Terns shares also jumped about 10% in after-hours trading on the news.

Why this matters for traders is simple. When a pharma giant starts paying up for oncology assets, the market often stops treating it as just 1 takeover story and starts seeing it as a wider signal. In this case, that signal is that large drugmakers may be willing to spend aggressively to replenish pipelines, especially in cancer, where blockbuster revenue gaps can bec ...